The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression

[1]  Johan Hartman,et al.  Estrogen receptor beta in breast cancer—Diagnostic and therapeutic implications , 2009, Steroids.

[2]  P. Munster,et al.  Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. , 2009, Cancer letters.

[3]  C. Nervi,et al.  Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. , 2009, The international journal of biochemistry & cell biology.

[4]  E. Biçaku,et al.  Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. , 2008, Cancer research.

[5]  T. Speed,et al.  Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene. , 2008, Molecular endocrinology.

[6]  K. Dahlman-Wright,et al.  Review Nuclear Receptor Signaling | The Open Access Journal of the Nuclear Receptor Signaling Atlas Estrogen receptor β: an overview and update , 2022 .

[7]  森嶌 祥子.  Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells , 2008 .

[8]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Southerland,et al.  Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. , 2007, Anticancer research.

[10]  T. Ruh,et al.  The effects of histone acetylation on estrogen responsiveness in MCF-7 cells , 1999, Endocrine.

[11]  P. Kushner,et al.  Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells , 2007, Breast Cancer Research and Treatment.

[12]  J. Bergh,et al.  Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer , 2007, Breast Cancer Research.

[13]  B. Katzenellenbogen,et al.  ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors. , 2006, Oncogene.

[14]  Raloxifene works as well as tamoxifen in preventing invasive breast cancer. , 2006, Mayo Clinic women's healthsource.

[15]  G. von Minckwitz,et al.  Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. , 2005, Endocrine-related cancer.

[16]  J. Zalcberg,et al.  Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance , 2005, Cancer biology & therapy.

[17]  Mitch Dowsett,et al.  Mechanisms of tamoxifen resistance. , 2004, Endocrine-related cancer.

[18]  R. Margueron,et al.  Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. , 2004, Biochemical pharmacology.

[19]  Eun Ryoung Jang,et al.  The histone deacetylace inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen , 2004 .

[20]  P. Pujol,et al.  Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. , 2004, Endocrine-related cancer.

[21]  Y. Sheen,et al.  Antiproliferative effect of trichostatin a and hc-toxin in T47D Human breast cancer cells , 2004, Archives of pharmacal research.

[22]  Eun Ryoung Jang,et al.  The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen , 2004, Oncogene.

[23]  Eun Ryoung Jang,et al.  The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. , 2004, Oncogene.

[24]  E. Lam,et al.  Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. , 2003, Oncogene.

[25]  J. Auwerx,et al.  PPARγ controls cell proliferation and apoptosis in an RB-dependent manner , 2003, Oncogene.

[26]  J. Auwerx,et al.  PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner. , 2003, Oncogene.

[27]  Y. Shang,et al.  Formation of the androgen receptor transcription complex. , 2002, Molecular cell.

[28]  N. McKenna,et al.  0013-7227/02/$15.00/0 Endocrinology 143(7):2461–2465 Printed in U.S.A. Copyright © 2002 by The Endocrine Society Minireview: Nuclear Receptor Coactivators—An Update , 2022 .

[29]  N. Rosen,et al.  The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. , 2001, Cancer research.

[30]  T. Heinzel,et al.  Histone deacetylase as a therapeutic target , 2001, Trends in Endocrinology & Metabolism.

[31]  R. Clarke,et al.  Cellular and molecular pharmacology of antiestrogen action and resistance. , 2001, Pharmacological reviews.

[32]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[33]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[34]  B. O’Malley,et al.  Steroid receptor coactivator-1 (SRC-1) enhances ligand-dependent and receptor-dependent cell-free transcription of chromatin. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Tripathy,et al.  Tamoxifen for early breast cancer: An overview of the randomised trials , 1999 .

[36]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[37]  C. Christiansen,et al.  EFFECTS OF RALOXIFENE ON BONE MINERAL DENSITY, SERUM CHOLESTEROL CONCENTRATIONS, AND UTERINE ENDOMETRIUM IN POSTMENOPAUSAL WOMEN , 1998 .

[38]  S. Minucci,et al.  A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  E. Barrett-Connor.  Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. , 1997, Circulation.

[40]  W R Greco,et al.  The search for cytotoxic synergy between anticancer agents: a case of Dorothy and the ruby slippers? , 1996, Journal of the National Cancer Institute.

[41]  S. Weitzman,et al.  Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  S. Oparil,et al.  Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. , 1996, Circulation.

[43]  L. Cheng,et al.  Effect of estradiol on accelerated atherosclerosis in rabbit heterotopic aortic allografts. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[44]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[45]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[46]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[47]  J. Manson,et al.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991, The New England journal of medicine.

[48]  S. Manuck,et al.  Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. , 1990, Arteriosclerosis.

[49]  T. Clarkson,et al.  Pregnancy‐Associated Inhibition of Coronary Artery Atherosclerosis in Monkeys: Evidence of a Relationship with Endogenous Estrogen , 1987, Arteriosclerosis.

[50]  S. Robinson,et al.  Species-specific pharmacology of antiestrogens: role of metabolism. , 1987, Federation proceedings.